Evidence map›Paper›PMID 26872481›Full record

ArticleEuropean biophysics journal : EBJ2016

TRPV1 channel as a target for cancer therapy using CNT-based drug delivery systems.

Andres Ortega-Guerrero, John M Espinosa-Duran, Jaime Velasco-Medina

Abstract read
PubMed Publisher
In one paragraph

Article in European biophysics journal : EBJ, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Andres Ortega-GuerreroSchool of Electrical and Electronics Engineering, Bionanoelectronics Research Group, Universidad del Valle, Cali, Colombia.
John M Espinosa-DuranDepartment of Chemistry, Center for Theoretical and Computational Nanoscience, Indiana University, Bloomington, IN, USA.
Jaime Velasco-MedinaSchool of Electrical and Electronics Engineering, Bionanoelectronics Research Group, Universidad del Valle, Cali, Colombia. jaime.velasco@correounivalle.edu.co.
Universidad del Valle · COIndiana University Bloomington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbon nanotubes are being considered for the design of drug delivery systems (DDSs) due to their capacity to internalize molecules and control their release. However, for cellular uptake of drugs, this approach requires an active translocation pathway or a channel to transport the drug into the cell. To address this issue, it is suggested to use TRPV1 ion channels as a potential target for drug release by nano-DDSs since these channels are overexpressed in cancer cells and allow the permeation of large cationic molecules. Considering these facts, this work presents three studies using molecular dynamics simulations of a human TRPV1 (hTRPV1) channel built here. The purpose of these simulations is to study the interaction between a single-wall carbon nanotube (SWCNT) and hTRPV1, and the diffusion of doxorubicin (DOX) across hTRPV1 and across a POPC lipid membrane. The first study shows an attractive potential between the SWCNT surface and hTRPV1, tilting the adsorbed SWCNT. The second study shows low diffusion probability of DOX across the open hTRPV1 due to a high free energy barrier. Although, the potential energy between DOX and hTRPV1 reveals an attractive interaction while DOX is inside hTRPV1. These results suggest that if the channel is dilated, then DOX diffusion could occur. The third study shows a lower free energy barrier for DOX across the lipid membrane than for DOX across hTRPV1. Taking into account the results obtained, it is feasible to design novel nano-DDSs based on SWCNTs to accomplish controlled drug release into cells using as translocation pathway, the hTRPV1 ion channel.

Indexed as

Molecular Targeted TherapyAnimalsAntineoplastic AgentsCell MembraneDoxorubicinDrug CarriersHumansLipid BilayersMolecular Dynamics SimulationNanotubes, CarbonPermeabilityPhosphatidylcholinesProtein ConformationRatsTRPV Cation Channels1-palmitoyl-2-oleoylphosphatidylcholineAntineoplastic AgentsDoxorubicinDrug CarriersLipid BilayersNanotubes, CarbonPhosphatidylcholinesTRPV1 protein, humanTRPV Cation ChannelsCarbon nanotubesDoxorubicinDrug delivery systemMolecular dynamicsTRPV1 channel

Identifiers

PMID26872481
OpenAlexW2340647435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.